then outcome prediction formula because these variables are not predictable on admission.

Results Mean age of symptomatic and asymptomatic CAS patients was 70.3 years (SD $\pm$ 10.6 years) with 20% > 80 years old; 39.5% females; 71.8% Whites, 4.5% Blacks and 4.1% Hispanics. 16.2% had symptomatic carotid stenosis. As chronic comorbidities, 75.7% had HTN, 32.1% DM, 58.1% HLD, 54.3% CAD, 0.6% CHF, 10.4% Atrial fibrillation/flutter 12.9% COPD, 11.4% chronic renal failure, 16.4% tobacco dependence, 0.4% alcohol dependence and 1.4% morbid obesity. As outcome makers, in-patient mortality was 1.1% (symptomatic 4.6%/asymptomatic 0.3%), 2% of patient had procedure related stroke (symptomatic 9.6%/asymptomatic 0.5%), discharge disposition to long term facility 9.4% (symptomatic 39.5%/asymptomatic 4.1%). Multiple outcome models developed to predict defined outcome markers to select the best predictable model. Several variables identified Age (greater than 80), presence of symptoms including TIA ($p < 0.001$), CHF ($p < 0.001$), COPD ($p < 0.001$) and CRF ($p < 0.001$) to formulate the best model. Long term facility disposition possibility = $0.012 + 0.067(1, \text{ if age } > 80, 0 \text{ if age } < 80) + 0.014(1, \text{ if DM}) + 0.084(1, \text{ if CHF}) + 0.03(1, \text{ if CRF}) + 0.030(1, \text{ if COPD}) + 0.351(1, \text{ if symptomatic})$ (Multiple linear regression, R^2 0.205)

Conclusions Age (greater than 80), presence of symptoms including TIA, DM, CHF, COPD and CRF were identified to predict worse functional outcome after CAS.

Disclosures S. Park: None. M. Alexander: 1; C; : Investigator in CREST2 Trial. A. Rosengart: None.

Oral Poster Abstracts

P-001 PERMANENT IMPLANTATION OF THE SOLITAIRE DEVICE AS A BAILOUT TECHNIQUE FOR LARGE VESSEL INTRACRANIAL OCCLUSIONS

¹J Houde, ²E Barber, ³M Kelly, ³L Peeling. ¹College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; ²General Surgery, University of Saskatchewan, Saskatoon, SK, Canada; ³Neurosurgery, University of Saskatchewan, Saskatoon, SK, Canada

10.1136/neurintsurg-2016-012589.43

Introduction The Solitaire (Medtronic, Minneapolis, MN) is a stentriever device for endovascular treatment of acute ischemic stroke (AIS). The Solitaire is well described for use in temporary endovascular bypass, and mechanical thrombectomy. Permanent placement of the Solitaire is an option, but there are limited reports to date. The authors of this study review six cases of Solitaire stent implantation in the setting of large vessel occlusion and acute ischemic stroke, where temporary endovascular bypass and mechanical thrombectomy failed.

Materials and methods Six cases of failed mechanical thrombectomy are reviewed, including procedural review, timing of anti-platelet agents, and radiographic and clinical outcomes.

Results Six patients with severe, acute ischemic stroke (AIS) and large vessel occlusion (LVO) were triaged to mechanical thrombectomy. Despite multiple attempts at mechanical thrombus retrieval with a combination of devices including stentriever and direct thrombus aspiration, flow could not be restored. As a bailout maneuver, the Solitaire stent was deployed and detached across the thrombus with TICI grade

3 flow restoration. All patients were loaded with full dose intra-arterial abciximab immediately after stent deployment and transitioned to dual antiplatelet therapy within 24 hours. There were no post-procedure hemorrhagic complications. All patients had significant neurological improvement post-procedure, with favorable modified Rankin scores at follow-up.

Conclusion With the recent over-whelming evidence demonstrating the effectiveness endovascular therapy in acute ischemic stroke, the expansion of stroke therapy requires that a variety of techniques be available to the operators. Permanent implantation of the Solitaire stent achieves adequate distal flow and good clinical outcomes in the setting of AIS. This case series suggests this technique provides a safe alternative for difficult cases refractory to other revascularization techniques.

Key Words stroke, revascularization, stent

Disclosures J. Houde: None. E. Barber: None. M. Kelly: 2; C; Medtronic. 4; C; Blockade. 6; C; Penumbra. L. Peeling: None.

P-002 INCIDENCE AND PROGNOSIS OF PLAQUE PROTRUSION DURING CAROTID ARTERY STENTING

¹K Takayama, ¹K Myouchin, ²T Wada, ³M Kotsugi, ³S Kurokawa, ⁴K Kichikawa. ¹Radiology and Interventional Neuroradiology, Ishinnkai Yao General Hospital, Yao City, Japan; ²Radiology, Nara Medical University, Kashihara city, Japan; ³Neurosurgery, Ishinnkai Yao General Hospital, Yao City, Japan; ⁴Radiology, Nara Medical University, Kashihara, Japan

10.1136/neurintsurg-2016-012589.44

Background Plaque protrusion (PP) is sometimes detected by angiography or intravascular ultrasound (IVUS) during carotid artery stenting (CAS). However, the incidence and prognosis of PP are unclear. Purpose: We investigated the incidence and prognosis of PP during CAS.

Material and Methods We retrospectively analyzed the case of 292 patients with 308 carotid artery stenoses (252 men; age: 39–97 years [mean: 73.4 years]; symptomatic stenosis: 137 lesions; mean stenosis rate: 78.4%) who underwent CAS and preoperative MR plaque imaging from October 2007 to October 2015. The incidence of plaque protrusion was evaluated by IVUS and angiography. The 30 day prognosis of PP and the incidence of ischemic lesions within 48 h after CAS were assessed using diffusion-weighted images. All CAS was performed using the standard procedure and embolic protection devices.

Result PP occurred in eight patients (2.6%). Stroke occurred in four patients (major: 1, minor: 3) (50.0%) in the PP groups. New ischemic lesions were observed in 87.5% (7/8) of the PP group. There were significant difference in the frequencies of stroke and ischemic lesions between the PP group and non-PP group. The detection of unstable plaque on MR plaque imaging and the use of open cell stent were significant predictive factors of PP.

Conclusion PP during CAS is strongly associated with ischemic complications. PP prevention is necessary to avoid ischemic complications during CAS.

Disclosures K. Takayama: 2; C; Medtronic. K. Myouchin: None. T. Wada: None. M. Kotsugi: None. S. Kurokawa: None. K. Kichikawa: None.